Genelux Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
01 avr. 2024 07h00 HE
|
Genelux Corporation
Genelux Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Nanomedicine Global Market to Observe Stupendous Growth at a CAGR of ~11% by 2028 | DelveInsight
09 janv. 2024 13h00 HE
|
DelveInsight Business Research LLP
New York, USA, Jan. 09, 2024 (GLOBE NEWSWIRE) -- Nanomedicine Global Market to Observe Stupendous Growth at a CAGR of ~11% by 2028 | DelveInsight Nanomedicine is experiencing heightened demand,...
Biopharmaceuticals Global Market is Expected to Surpass 700 Billion Mark by 2028, Assesses DelveInsight
02 janv. 2024 13h00 HE
|
DelveInsight Business Research LLP
New York, USA, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Biopharmaceuticals Global Market is Expected to Surpass 700 Billion Mark by 2028, Assesses DelveInsight The demand for biopharmaceuticals is...
Genelux Corporation Receives FDA Fast Track Designation for Olvi-Vec in Platinum Resistant/Refractory Ovarian Cancer
27 nov. 2023 07h00 HE
|
Genelux Corporation
Genelux Corporation Receives FDA Fast Track Designation for Olvi-Vec in Platinum Resistant/Refractory Ovarian Cancer
Intratumoral Cancer Therapies Market to Observe Stupendous Growth During the Forecast Period (2023–2032), Assesses DelveInsight | Key Players - Nanobiotix, Sirnaomics, Apexigen, Replimune, Merck, OncoSec, DNAtrix, Treovir Istari
15 nov. 2023 13h00 HE
|
DelveInsight Business Research LLP
New York, USA, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Intratumoral Cancer Therapies Market to Observe Stupendous Growth During the Forecast Period (2023–2032), Assesses DelveInsight | Key Players -...
Genelux Corporation Reports Third Quarter 2023 Financial Results and Provides General Business Updates
14 nov. 2023 17h50 HE
|
Genelux Corporation
- Expanded executive team as Lourie Zak appointed Chief Financial Officer - - Extended clinical focus on systemic administration in small cell lung cancer - - $29.9 million in cash and equivalents...
Genelux Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
14 sept. 2023 07h00 HE
|
Genelux Corporation
WESTLAKE VILLAGE, Calif., Sept. 14, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that on September 11, 2023, the...
Genelux Corporation to Present at the H.C. Wainwright Global Investment Conference
07 sept. 2023 16h01 HE
|
Genelux Corporation
WESTLAKE VILLAGE, Calif., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President,...
Genelux Corporation Announces New Chief Financial Officer
28 août 2023 07h00 HE
|
Genelux Corporation
WESTLAKE VILLAGE, Calif., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Lourie S. Zak will join the...
Genelux Corporation Reports Second Quarter 2023 Financial Results and Provides General Business Updates
14 août 2023 07h00 HE
|
Genelux Corporation
- Inclusion into the broad-market Russell 3000® Index and small-cap Russell 2000® Index - - Publication of VIRO-15 Phase 2 data in JAMA Oncology - - $51 Million raised after closing of two...